menu search

Intellia's (ntla) ind for gene-editing therapy gets fda clearance

Intellia (NTLA) gets FDA nod to begin a phase iii study on its gene editing candidate, NTLA-2001 to tre...

October 19, 2023, 12:47 pm

Annovis (anvs) ad study to continue as planned, shares rise

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/iii ...

October 13, 2023, 2:16 pm

Biocardia (bcda) up on plans for second heart failure study

BioCardia (BCDA) completes enrollment in a pivotal phase iii study on its CardiAMP cell therapy for the...

October 12, 2023, 12:47 pm

Roche's (rhhby) vabysmo positive in late-stage rvo studies

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase ...

October 10, 2023, 1:32 pm

Novartis (nvs) announces positive data on kidney disease drug

Novartis' (NVS) phase iii study on pipeline candidate iptacopan in patients with IgAN shows superiority...

October 3, 2023, 1:32 pm

Roche to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd

Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine ki...

October 2, 2023, 1:00 am

Baudax bio shares rocket as lead clinical candidate gains fda orphan drug designation

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug stat...

September 28, 2023, 12:27 pm

Novartis (nvs) lutathera meets primary goal in phase iii study

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line adva...

September 25, 2023, 1:32 pm

Jazz pharma (jazz) gets eu nod for cancer drug enrylaze

The approval is based on data from a phase II/iii study, which showed that treatment with Jazz's (JAZZ)...

September 22, 2023, 1:31 pm

Relmada (rlmd) up on positive data for anti-depressant candidate

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase iii study of its le...

September 21, 2023, 3:02 pm

Cymabay (cbay) stock up on positive results from pbc study

CymaBay (CBAY) reports encouraging data from the phase iii study of seladelpar in PBC patients. Stock u...

September 8, 2023, 2:17 pm

G-iii apparel stock soars after a big earnings beat, license deal to produce champion outerwear

Shares of G-III Apparel Group Ltd. Giii shot up 14.8% toward a 13-month high in premarket trading Thurs...

September 7, 2023, 7:43 am

Biocardia (bcda) dips 26% on flunking heart failure study

Based on one-year follow-up data from a pivotal phase iii study, BioCardia (BCDA) reveals that its Card...

September 6, 2023, 12:01 pm

Marijuana's reclassification is 'long overdue' by the dea: curaleaf ceo

Following urgings by the U.S. Department of Health & Human Services, DEA officials could reclassify marijuana's drug status to that of a Schedule ...

September 4, 2023, 10:00 am

Pot stocks rally after health officials ask dea to reclassify marijuana as lower-risk drug

Assistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a sche...

August 30, 2023, 4:56 pm

Kodiak (kod) down as late-stage dme studies fail

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase iii studies evaluating ta...

July 25, 2023, 10:53 am

Curium announces publication of [18f]dcfpyl versus [18f]fluoromethylcholine results from european phase iii study (python trial)

PARIS, July 21, 2023 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, ...

July 21, 2023, 7:30 am

Lilly's (lly) donanemab slows alzheimer's disease progression

Data from a phase iii study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and ...

July 18, 2023, 12:50 pm

Seelos: 2 catalysts before end of 2023 make this a must watch

Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be rel...

July 12, 2023, 7:09 pm

Incyte's (incy) opzelura meets goal in phase iii pediatric study

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase iii study in childre...

July 12, 2023, 12:34 pm


Search within

Pages Search Results: